ACM
IBRX icon

Akanthos Capital Management’s ImmunityBio IBRX Stock Holding History

Akanthos Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-26,330
Closed -$93K – 12
2017
Q1 		$93K Hold
26,330
– – 0.11% 12
2016
Q4 		$135K Hold
26,330
– – 0.11% 15
2016
Q3 		$205K Buy
+26,330
New +$197K 0.2% 18

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Akanthos Capital Management's IBRX Position: Q2 2017 in Review

Akanthos Capital Management sold out of ImmunityBio (IBRX) in Q2 2017, closing a stake of 26,330 shares — an estimated $93K sold.

Akanthos Capital Management first reported a position in IBRX in Q3 2016 and held it in 3 quarters. The position peaked at $205K in Q3 2016. 58 funds tracked by Wall St. Rank hold IBRX as of Q2 2017.

  • Akanthos Capital Management reported no remaining ImmunityBio position as of Q2 2017 after selling out during the quarter.
  • Akanthos Capital Management sold 26,330 ImmunityBio shares in Q2 2017, an estimated $93K.
  • Akanthos Capital Management first reported a position in ImmunityBio in Q3 2016 and held it in 3 quarters.
  • Akanthos Capital Management's ImmunityBio position peaked at $205K in Q3 2016.
  • 58 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2017.

Based on Akanthos Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.